Jazz settles narcolepsy patent row with generics

Jazz Pharmaceuticals has dropped its claims against Ranbaxy, Sun Pharmaceutical and Ohm in a patent infringement case involving  narcolepsy drug Xyrem (sodium oxybate).

Jazz told the US District Court for the District of New Jersey that it had reached agreements with the companies.

Ranbaxy, Sun and Ohm were sued in 2013 after their generic versions of Xyrem were alleged to have infringed several of Jazz’s patents. However, the companies have now agreed not to manufacture or to sell the generic drugs while the patents are still valid.

The dispute arose in response to the filing of Abbreviated New Drug Applications by all three companies seeking approval to market a generic version of Xyrem.

Some of the generic makers involved in the dispute with Jazz had claimed that the patents were invalid.